In these uncertain times portfolios benefit from firms with regulatory barriers to new competitors entering their markets, predictable growth and appealing dividend yields of around 4%. A good example is which was founded in 2003 and admitted to Aim in 2014. It specialises in creating and manufacturing sheep monoclonal antibodies (SMAs) for use in immunodiagnostics. Monoclonal antibodies bolster
Medical promise at a reasonable price
Dec 15, 2023
2 minutes
You’re reading a preview, subscribe to read more.
Start your free 30 days